SGLT2 Inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
George Vasquez-Rios,1 Girish N Nadkarni1,2 1Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 2The Charles Bronfman Institute of Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USACorrespondence: Giri...
Main Authors: | Vasquez-Rios G, Nadkarni GN |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-10-01
|
Series: | International Journal of Nephrology and Renovascular Disease |
Subjects: | |
Online Access: | https://www.dovepress.com/sglt2-inhibitors-emerging-roles-in-the-protection-against-cardiovascul-peer-reviewed-article-IJNRD |
Similar Items
-
Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
by: Liwen Bao, et al.
Published: (2021-09-01) -
New SGLT2 inhibitor ertugliflozin: safe and effective in the management of type 2 diabetes
by: V. V. Salukho, et al.
Published: (2020-05-01) -
Class effect for SGLT-2 inhibitors: a tale of 9 drugs
by: Dario Giugliano, et al.
Published: (2019-07-01) -
Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
by: Alex Ali Sayour, et al.
Published: (2021-09-01) -
Cardiovascular Outcome in Patients Treated With SGLT2 Inhibitors for Heart Failure: A Meta-Analysis
by: Gloria M. Gager, et al.
Published: (2021-07-01)